GlaxoSmithKline PLC has agreed in principle with the US government on a $3 billion settlement of investigations into the companys sales and marketing practices, the drug maker said Thursday
The agreement is expected to be completed next year, and the settlement will be paid through the companys cash resources, GSK said
The company said the proposed settlement covered its sales and marketing practices for drugs including antidepressants Paxil and Wellbutrin, an investigation begun by the US Attorneys office of Colorado in 2004 and later taken over by the US Attorneys Office of Massachusetts; the US Justice Departments investigation of possible inappropriate use of the nominal price exception under the Medicaid Rebate Program; and the Justice Departments investigation of the development and marketing of the diabetes drug Avandia
GSK shares were up 16 percent at 1,377 pence $2199 in late trading on the London Stock Exchange
The company said the tentative settlement covers both civil and criminal liabilities
This is a significant step toward resolving difficult, long-standing matters which do not reflect the company that we are today, CEO Andrew Witty said
In recent years, we have fundamentally changed our procedures for compliance, marketing and selling in the US to ensure that we operate with high standards of integrity and that we conduct our business openly and transparently
Among those steps, the company no longer bases bonuses on individual sales targets, GSK said, but on quality of service
In its annual report for 2010, GlaxoSmithKline said it had made a provision of $4 billion for legal and other disputes, double the 2009 figure
In June, Glaxos US subsidiary agreed to pay more than $40 million to 37 US states and Washington, DC, to settle complaints about manufacturing processes at a plant in Puerto Rico, which has been closed
The company also paid a $750 million fine in 2010 in the US related to the Puerto Rico plant